Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderat
 

Avexxin AS, a therapeutic company focusing on the discovery and development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the completion of a second phase I/IIa study showing Proof-of-Concept in man.

More...